Phase 2 N=26 Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level. — -695.2; 216.7 U/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
CML
Primary: Percentage of Participants Without Molecular Relapse Within 6 Months After Starting the TFR Phase — 12 Participants
Phase 2 N=74 Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Phase 2 N=25 Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers
Tobacco Use Cessation · Cancer Prevention
Primary: Intervention Feasibility & Acceptability — 4.87; 4.71; 4.83 score on a scale
Phase 2 N=7 A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
Beta-Thalassemia Major · Sickle Cell Disease
Primary: Number of Treated Participants With Successful Neutrophil and Platelet Engraftment — 3; 4; 3; 4 Participants
Phase 2 N=111 Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Event Free Survival — 3.48; 4.96 months
Phase 2 N=75 Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery
Pelvic Organ Prolapse · Surgery · Postoperative Pain
Primary: Primary Postoperative Pain Measured by the Numerical Rating Scale (NRS) — 3.0; 4.0; 3.75 score on a scale — p=0.39
Phase 2 N=19 Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation
Insulin Resistance
Primary: Percent Change in Hepatic Insulin Sensitivity — -19.2; 5.8; -33.66; 113.7 percent change
Phase 2 N=13 Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Renal Cell Carcinoma
Primary: The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest — 0 Participants
Phase 2 N=78 A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Agitation and Aggression in Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 53 Participants
Phase 2 N=30 A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
Cystic Fibrosis
Primary: Change From Baseline in Total Chloride Transport at Day 14 of Cycles 1 and 2 — 1.45; 0.66; -2.81; -2.69 millivolts (mV) — p=0.133
Phase 2 N=11 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Phase 2 N=56 Power Training Post-stroke
Stroke
Primary: Gait Speed — 0.51 meters per second
Phase 2 N=66 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Ulcerative Colitis · Digestive System Diseases · Colitis, Ulcerative
Primary: Number of Subjects With Treatment-related Adverse Events — 5; 7; 7; 14 Participants
Phase 2 N=31 Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Adult Type Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma · Ovarian Sertoli-Leydig Cell Tumor
Primary: Probability of Complete Clinical Response — 3.2 Percentage of Participants